Eupraxia Pharmaceuticals (EPRX) Return on Sales (2023 - 2025)
Eupraxia Pharmaceuticals' (EPRX) quarterly Return on Sales came in at 0.19% in Q1 2025, down 12.0% year-on-year from 0.21% in Q1 2024, and down 163.69% on a QoQ basis from 0.07% in Q1 2024.
Eupraxia Pharmaceuticals (EPRX) Return on Sales (2023 - 2025) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has 3 years of Return on Sales data on file, last reported at 0.19% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn | 0.00% |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 0.00% |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn | 0.00% |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn | 0.00% |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - | - |
| 10 | Eupraxia Pharmaceuticals | 351.62 Mn | 351.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -0.19% |
| Mar 31, 2024 | -0.07% |
| Mar 31, 2023 | 0.31% |